Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- PharmaEssentia Eyes Japan Sales of 50 Billion Yen in 2030
June 16, 2023
- Astellas Inks Protein Degrader Deal with Cullgen
June 16, 2023
- Opdivo Filed for Malignant Epithelial Tumors in Japan
June 16, 2023
- Azilva, Allermist Authorized Generics to Hit Japan Market on June 16
June 16, 2023
- Japan Regenerative Drug Market to Reach 72.3 Billion Yen in 2030: Fuji Keizai
June 16, 2023
- Ohara’s Cancer Med Erwinase Reaches Japan Market Over 6 Years after Approval
June 15, 2023
- Chugai Files NDA for PNH Drug Crovalimab in Japan
June 15, 2023
- AstraZeneca Launches Sales Unit Dedicated to GI Cancer as Imfinzi Expands Label
June 14, 2023
- AbbVie Goes Solo in Humira Marketing and Promotion in Japan
June 14, 2023
- Argenx Makes World’s 1st Filing in Japan for Vyvgart’s ITP Use
June 14, 2023
- Keytruda Filed for Biliary Tract Cancer in Japan
June 14, 2023
- Lilly, Mitsubishi Tanabe Roll Out Mounjaro’s High-Dose Versions
June 13, 2023
- US District Court Rejects Claim for Myrbetriq Patent Infringement, Astellas to Challenge Ruling
June 13, 2023
- Shionogi Kicks Off Global PEP Study of Xocova; NDA for Full Approval Filed in Japan
June 12, 2023
- Astellas Files Zolbetuximab for CLDN18.2-Positive Gastric Cancer in Japan
June 12, 2023
- ASKA, RaQualia Wind Up Ion Channels Collab
June 12, 2023
- FDA Advisors Back Full Approval of Eisai’s Alzheimer’s Med
June 12, 2023
- AstraZeneca Crowned in Foreign Pharma Ranking for 2nd Year Straight, Followed by MSD
June 9, 2023
- Ceolia Pharma’s Comlex Otic Solution Now Available in Japan
June 9, 2023
- Takeda Rolls Out Low-Dose Form of SBS Therapy Revestive in Japan
June 9, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…